{
  "meta": {
    "timestamp": "2025-01-06T09:37:14.973110",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "ASTELLAS PHARMA NPV",
      "symbol": "ALPMY",
      "analysis": {
        "historical": {
          "risk_score": 65,
          "key_risks": [
            "Pricing and access issues, particularly for Xtandi, due to Medicare price negotiations and high drug costs",
            "Patent expirations and legal challenges, including the invalidation of a key patent for Myrbetriq",
            "Clinical trial setbacks, especially in gene therapy programs like AT132, raising safety concerns",
            "Regulatory risks, including delays in approvals and compliance issues in a highly regulated industry"
          ],
          "controversies": [
            "Criticism over the high cost of Xtandi and its exclusion from Medicare price negotiations",
            "Legal challenges and patent disputes, such as the invalidation of Myrbetriq's patent",
            "Safety concerns in gene therapy trials, including a participant death in the ASPIRO trial"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Access to affordable medications, particularly for critical treatments like Xtandi",
            "Patient safety concerns in clinical trials, especially in gene therapy programs"
          ],
          "governance_issues": [
            "Dependence on a few key products, leading to revenue concentration risk",
            "Leadership changes, with the appointment of a new CEO in 2023, introducing potential strategic shifts"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Astellas pulls IRA lawsuit after avoiding CMS negotiation list",
              "snippet": "When CMS last week revealed its list of the first 10 drugs eligible for Medicare price negotiations, Astellas' Xtandi did not make the cut. This surprised some pharma watchers, who had expected ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142332+00:00",
              "published_date": null,
              "source_hash": "eceae5fee5a7abacfb9bfcad886ab529"
            },
            {
              "url": "",
              "title": "Business Results | Astellas Pharma Inc.",
              "snippet": "You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142440+00:00",
              "published_date": null,
              "source_hash": "ef9a8fe0b8b5ded05227d4433d623c65"
            },
            {
              "url": "",
              "title": "Astellas Pharma Inc. (ALPMY) Stock Price & Overview - Stock Analysis",
              "snippet": "About Astellas Pharma. Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142454+00:00",
              "published_date": null,
              "source_hash": "5b691f9071780f345e7f444c48d70d75"
            },
            {
              "url": "",
              "title": "Investor Relations | Astellas Pharma Inc.",
              "snippet": "Astellas invests approximately 18.3% of its revenue in R&D\u2014well above the average for the pharmaceutical industry (For the fiscal year ended in March 2024). Drug Research Astellas has a lot of programs undergoing R&D.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142467+00:00",
              "published_date": null,
              "source_hash": "33b600064c9d85c22207a8a98252c4c6"
            },
            {
              "url": "",
              "title": "Astellas Pharma (ALPMY) Market Cap & Net Worth - Stock Analysis",
              "snippet": "Astellas Pharma has a market cap or net worth of $17.48 billion as of January 3, 2025. Its market cap has decreased by -21.36% in one year. Market Cap 17.48B. ... Formula: Market Cap = Stock Price * Shares Outstanding. Full Definition. Related Stocks. Company Market Cap; Veradigm: 1.54B: SS Innovations International: 1.33B: Elite ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142483+00:00",
              "published_date": null,
              "source_hash": "9af7f1708ed5e8f03859109d06b57831"
            },
            {
              "url": "",
              "title": "Astellas Pharma Revenue - Stock Analysis",
              "snippet": "Astellas Pharma had revenue of 462.50B JPY in the quarter ending September 30, 2024, with 17.94% growth. This brings the company's revenue in the last twelve months to 1.77T, up 16.32% year-over-year. In the fiscal year ending March 31, 2024, Astellas Pharma had annual revenue of 1.60T with 5.60% growth.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142493+00:00",
              "published_date": null,
              "source_hash": "f300332272c718761914024a418ebe46"
            },
            {
              "url": "",
              "title": "Astellas Pharma (TSE:4503) - Stock Price, News & Analysis - Simply Wall St",
              "snippet": "Research Astellas Pharma's (TSE:4503) stock price, latest news & stock analysis. Find everything from its Valuation, Future Growth, Past Performance and more. ... European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142503+00:00",
              "published_date": null,
              "source_hash": "30c303000a02b13e6f83970114d4a184"
            },
            {
              "url": "",
              "title": "Financial Information | Astellas Pharma Inc.",
              "snippet": "You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142514+00:00",
              "published_date": null,
              "source_hash": "16a6a1408ab6fde3acafa72908677b76"
            },
            {
              "url": "",
              "title": "Astellas Pharma (DB:YPHA) - Stock Price, News & Analysis - Simply Wall St",
              "snippet": "Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142522+00:00",
              "published_date": null,
              "source_hash": "173b1db5c11e1be65c91146c9858f5ed"
            },
            {
              "url": "",
              "title": "Astellas Pharma Inc. (ALPMY) - Yahoo Finance",
              "snippet": "Find the latest Astellas Pharma Inc. (ALPMY) stock quote, history, news and other vital information to help you with your stock trading and investing.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "retrieved_at": "2025-01-06T16:36:43.142531+00:00",
              "published_date": null,
              "source_hash": "5b2ddff1d8a9ddaa95aa75b0d2c72875"
            },
            {
              "url": "",
              "title": "Home | Astellas Clinical Trials",
              "snippet": "Our VISION at Astellas is to turn innovative science into VALUE for patients. The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complet",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059455+00:00",
              "published_date": null,
              "source_hash": "16a513329494469c60b4011d1d1a937e"
            },
            {
              "url": "",
              "title": "News - Astellas Pharma Inc. - Astellas Gene Therapies",
              "snippet": "TOKYO, Sept. 14, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., \"Astellas\") reports that the ASPIRO clinical trial participant, who developed a serious adverse event as described on Sept. 1, passed away on Sept. 9. The cause of death is still pending. Astellas is gathering the relevant clinical information and incorporating such information into the ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059591+00:00",
              "published_date": null,
              "source_hash": "fde6153c75cc8ab9c7c7a83fcac532cf"
            },
            {
              "url": "",
              "title": "Clinical Trials | Astellas Pharma Inc.",
              "snippet": "To learn more about Astellas clinical trials, what they are and what it means to participate in a clinical trial, please visit Astellas Clinical Trials. Astellas is committed to public disclosure of clinical trial information and data transparency for Astellas-sponsored clinical trials. If you are interested in viewing results of an Astellas ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059627+00:00",
              "published_date": null,
              "source_hash": "68c404f7aab3162e398c3e9cb938fb73"
            },
            {
              "url": "",
              "title": "Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients ...",
              "snippet": "This decision follows the reporting of a recent serious adverse event (SAE) in a study participant due to abnormal liver function tests (LFTs) observed in the weeks following dosing of the AT132 investigational gene therapy product at a lower dose (1.3x10 14 vg/kg). Astellas voluntarily halted screening and dosing, reported the SAE to regulatory agencies, and is engaged in dialogue with ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059655+00:00",
              "published_date": null,
              "source_hash": "f16b58a545e552b312325493b5b08386"
            },
            {
              "url": "",
              "title": "News | Astellas Pharma Inc.",
              "snippet": "TOKYO, September 1, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., \"Astellas\") announced that it has voluntarily paused screening and dosing of additional participants in its ASPIRO clinical trial evaluating AT132 in patients with X-linked Myotubular Myopathy (XLMTM).. This decision follows the reporting of a recent serious adverse event (SAE) in a study ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059679+00:00",
              "published_date": null,
              "source_hash": "796261fdd8851d44bb4006b90a8d1b84"
            },
            {
              "url": "",
              "title": "News - Astellas Pharma Inc.",
              "snippet": "Nov 15, 2023 - Preliminary data analysis on ventilator dependence and motor improvement are reported alongside overall safety findings- TOKYO, November 15, 2023 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") today announced that The Lancet Neurology published a preliminary data analysis from the ASPIRO trial, evaluating the safety and efficacy of ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059703+00:00",
              "published_date": null,
              "source_hash": "6e9b3e08f12bf48b08e7665ca9ec8a1b"
            },
            {
              "url": "",
              "title": "Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients ...",
              "snippet": "In the U.S., an IND clinical hold is an order issued by the U.S. Food and Drug Administration (FDA) to the sponsor of a clinical trial to delay a proposed clinical trial or suspend an ongoing ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059727+00:00",
              "published_date": null,
              "source_hash": "8aae26504421b6dafa403d78183b3a2f"
            },
            {
              "url": "",
              "title": "Clinical Trials | Astellas Pharma US | Innovation",
              "snippet": "To learn more about Astellas clinical trials, what they are and what it means to participate in a clinical trial, please visit Astellas Clinical Trials. Astellas is committed to public disclosure of clinical trial information and data transparency for Astellas-sponsored clinical trials. If you are interested in viewing results of an Astellas ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059749+00:00",
              "published_date": null,
              "source_hash": "e1ea0af09db824b10cf8b5403446b883"
            },
            {
              "url": "",
              "title": "Astellas finds underlying liver issues in gene therapy deaths",
              "snippet": "Astellas has shared a detailed look at the four deaths in its AT132 gene therapy clinical trial. Writing in The Lancet Neurology, the drugmaker explained that the liver toxicity seen in the trial ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059770+00:00",
              "published_date": null,
              "source_hash": "4a181525aa83e1df4c05e50f2976a3d2"
            },
            {
              "url": "",
              "title": "Clinical Trial Results and Summaries: What to Know | Astellas",
              "snippet": "About Clinical Trials Results Summaries. Publishing clinical trial results helps the research community understand both progress and setbacks in medical research. However, plain language summaries (PLS) help the general public understand clinical trial results. These summaries contain information about therapies that may still be under ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "retrieved_at": "2025-01-06T16:36:48.059803+00:00",
              "published_date": null,
              "source_hash": "e8eb9e81c689c3aa3110d393b3e377ec"
            },
            {
              "url": "",
              "title": "News | Astellas Pharma Inc.",
              "snippet": "Astellas Confirms Unfavorable District Court Decision in Myrbetriq \u00ae U.S. Patent Trial. Important Notice. ... TOKYO, June 12, 2023 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, \"Astellas\") confirmed the U.S. District Court for the District of Delaware issued a decision on June 9 finding U.S. Patent No. 10,842,780 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917658+00:00",
              "published_date": null,
              "source_hash": "2c58ba3a259f359a18cc4d58a595c6f4"
            },
            {
              "url": "",
              "title": "Astellas hit by US patent verdict for incontinence drug",
              "snippet": "A US district court has said that a key patent held by Astellas on its Myrbetriq drug for urinary incontinence is invalid, in a setback to its efforts to defend the blockbuster therapy from ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917799+00:00",
              "published_date": null,
              "source_hash": "4c04b2302b818b856d4aba9e78abdaad"
            },
            {
              "url": "",
              "title": "BRIEF\u2014Unfavorable US patent decision for Astellas' Myrbetriq",
              "snippet": "The US District Court for the District of Delaware has issued a decision finding that Japanese drug major Astellas Pharma's US Patent No 10,842 on Myrbetriq (mirabegron), which expires in March 2030, is invalid, the company confirmed today. The '780 Patent covers extended-release drug formulations of mirabegron, including Myrbetriq.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917833+00:00",
              "published_date": null,
              "source_hash": "fd40c8a306e0f7f4bda0120079f1af1d"
            },
            {
              "url": "",
              "title": "Myrbetriq Patent Expiration - GreyB",
              "snippet": "The earliest legal proceeding was initiated on Oct 16, 2017, against patent number US6346532. The petitioner Sawai Pharmaceutical Co., Ltd., challenged the validity of this patent, with Astellas Pharma Inc. as the respondent. Click below to track the latest information on how companies are challenging Myrbetriq's patents.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917864+00:00",
              "published_date": null,
              "source_hash": "9adc9c2c68ed6b459f0e141d08965fdb"
            },
            {
              "url": "",
              "title": "Astellas' Patent on Myrbetriq ER Nixed After 'Zealous Defense'",
              "snippet": "Astellas Pharma Inc. lost a ruling that canceled a patent for its overactive-bladder treatment Myrbetriq, potentially opening the door to generic versions of the drug's extended-release formulation nearly six years before the patent's expiration. Judge Joseph F. Bataillon wrote that Astellas' \"zealous defense has conceded more fundamental ground,\" rendering US Patent No. 10,842,780 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917889+00:00",
              "published_date": null,
              "source_hash": "caff8c6541a19b78a546b5dad2f8666f"
            },
            {
              "url": "",
              "title": "When will the patents on MYRBETRIQ expire, and when will generic ...",
              "snippet": "MYRBETRIQ patent expiration dates, patent landscape, 505(b)2 developments, ... Astellas Pharma Europe B.V. Betmiga: ... Astellas, the manufacturer of Myrbetriq, has seen varied financial performance in recent years. While the company's revenue has increased, operating profit and core profit have declined due to factors such as increased selling ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.917914+00:00",
              "published_date": null,
              "source_hash": "581bf4addccf015be59a402ef1de727e"
            },
            {
              "url": "",
              "title": "Astellas Files Complaint Against Pharmaceutical Companies for Alleged ...",
              "snippet": "The patent in question, deemed the '780 patent, corresponds to APGD's Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.918008+00:00",
              "published_date": null,
              "source_hash": "05b51fcfeaf2361d3e047aacc9f9963c"
            },
            {
              "url": "",
              "title": "Astellas Pharma Alleges Infringement of Myrbetriq Patent Against ...",
              "snippet": "Astellas Pharma, as owner of United States Patent No. 10,842,780, covering overactive bladder treatment drug Myrbetriq, along with patent-in-suit licensee Astellas Ireland Co. Ltd. and Myrbetriq ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.918031+00:00",
              "published_date": null,
              "source_hash": "6c251985e1c384a056a6d7c5f2143b5f"
            },
            {
              "url": "",
              "title": "ASTELLAS PHARMA, INC. v. SANDOZ INC. , No. 23-2032 (Fed. Cir. 2024)",
              "snippet": "Astellas Pharma, Inc. and its affiliates (collectively, \"Astellas\") sued Sandoz Inc. and other defendants for patent infringement related to their attempts to market generic versions of Myrbetriq\u00ae, a drug used to treat overactive bladder. The patent in question, U.S. Patent 10,842,780, covers sustained-release formulations of mirabegron, which Astellas developed to mitigate the drug's ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.918052+00:00",
              "published_date": null,
              "source_hash": "fb021a2ab5d2cc76e7131a5c34414408"
            },
            {
              "url": "",
              "title": "Astellas patent survives 'natural law' decision | BioWorld",
              "snippet": "The U.S. Court of Appeals for the Federal Circuit reined in a district court that invalidated three claims in an Astellas Pharma Inc. patent protecting bladder drug Myrbetriq (mirabegron) based on a issue that was never argued.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "ASTELLAS PHARMA NPV ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "retrieved_at": "2025-01-06T16:36:51.918078+00:00",
              "published_date": null,
              "source_hash": "661060d7af77d1183d678ad85f6064b6"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "ASTELLAS PHARMA NPV pricing controversies Xtandi",
              "rationale": "Investigate ongoing legal and financial risks related to drug pricing, particularly for Xtandi, which has faced scrutiny in the U.S. market.",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "ASTELLAS PHARMA NPV clinical trial safety concerns AT132",
              "rationale": "Examine ethical and social concerns related to safety issues in clinical trials for AT132, a gene therapy program.",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "ASTELLAS PHARMA NPV patent expirations Prograf Myrbetriq",
              "rationale": "Assess financial risks associated with upcoming patent expirations for key products like Prograf and Myrbetriq, which could lead to generic competition.",
              "priority": 1
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T09:37:14.973117",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}